417 related articles for article (PubMed ID: 22015300)
21. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
22. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2011 Aug; 128(3):633-41. PubMed ID: 20803240
[TBL] [Abstract][Full Text] [Related]
23. Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer.
Strand C; Ahlin C; Bendahl PO; Fjällskog ML; Hedenfalk I; Malmström P; Fernö M
Breast Cancer Res Treat; 2012 Jan; 131(1):33-40. PubMed ID: 21331623
[TBL] [Abstract][Full Text] [Related]
24. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
25. Personalized medicine: the road ahead.
Mehta R; Jain RK; Badve S
Clin Breast Cancer; 2011 Mar; 11(1):20-6. PubMed ID: 21421518
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
27. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
28. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
29. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Abu-Khalf M; Pusztai L
Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
[TBL] [Abstract][Full Text] [Related]
30. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
31. Predicting features of breast cancer with gene expression patterns.
Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
[TBL] [Abstract][Full Text] [Related]
32. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
33. Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
Glück S; Yip AY; Ng EL
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S17-22. PubMed ID: 22316427
[TBL] [Abstract][Full Text] [Related]
34. Impact of gene expression profiling tests on breast cancer outcomes.
Marchionni L; Wilson RF; Marinopoulos SS; Wolff AC; Parmigiani G; Bass EB; Goodman SN
Evid Rep Technol Assess (Full Rep); 2007 Dec; (160):1-105. PubMed ID: 18457476
[TBL] [Abstract][Full Text] [Related]
35. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
36. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
37. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
Markopoulos C
Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
[TBL] [Abstract][Full Text] [Related]
38. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
Blok EJ; Bastiaannet E; van den Hout WB; Liefers GJ; Smit VTHBM; Kroep JR; van de Velde CJH
Cancer Treat Rev; 2018 Jan; 62():74-90. PubMed ID: 29175678
[TBL] [Abstract][Full Text] [Related]
39. European inter-institutional impact study of MammaPrint.
Cusumano PG; Generali D; Ciruelos E; Manso L; Ghanem I; Lifrange E; Jerusalem G; Klaase J; de Snoo F; Stork-Sloots L; Dekker-Vroling L; Lutke Holzik M
Breast; 2014 Aug; 23(4):423-8. PubMed ID: 24685596
[TBL] [Abstract][Full Text] [Related]
40. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients.
Naoi Y; Kishi K; Tsunashima R; Shimazu K; Shimomura A; Maruyama N; Shimoda M; Kagara N; Baba Y; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2013 Jul; 140(2):299-306. PubMed ID: 23884597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
